Advancement of Poly-(ADP – Ribose) Polymerase (PARP) Inhibitors in Cancer Progression and Treatment
Abstract
Keywords
Full Text:
PDFReferences
O’Brien PJ. Catalytic Promiscuity and the Divergent Evolution of DNA Repair Enzymes. Chem. Rev. 2006; 106 (2):720–52p. [Pub Med: 16464022]
Gudmundsdottir K, Ashworth A. The Roles of BRCA1 and BRCA2 and associated Proteins in the Maintenance of Genomic Stability. Oncogene. 2006; 25(43):5864–74p. [Pub Med: 16998501]
Hottiger MO, Hassa PO, Luscher B, et al. Toward a Unified Nomenclature for Mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010; 35 (4):208–19p.doi:10.1016/j.tibs.2009.12.003.
Steffen JD, Pascal JM. New Players to the Field of ADP-Ribosylation Make the Final Cut. EMBO J. 2013; 32 (9):1205–7p.doi:10.1038/emboj.2013.83.
Dantzer F, Schreiber V, Niedergang C, et al. Involvement of Poly-(ADP ribose) Polymerase in Base Excision Repair. Biochimie. 1999; 81 (1–2):69–75p. [Pub Med: 10214912]
W.-M. Tong, U. Cortes, Z.-Q. Wang. Poly-(ADP-ribose) Polymerase: A Guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta. 2001; 1552(1): 27–37p.
Fortini P, Pascucci B, Parlatini E, et al. The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie. 2003; 85 (11):1053–71p. [Pub Med: 14726013].
Hochegger H, Dejsuphong D, Fukushima T, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J. 2006; 25 (6):1305–14p. [PubMed: 16498404].
Steffen JD, Brody JR, Armen RS, Pascal JM. Structural Implications for Selective Targeting of PARPs. Front Oncol. 2013; 3:301. doi:10.3389/fonc.2013.00301.
Sugo N, Niimi N, Aratani Y, et al. Decreased PARP-1 levels accelerate embryonic lethality but attenuate neuronal apoptosis in DNA polymerase β-deficient mice. Biochem Biophys Res Commun. 2007; 354(3):656–61p.
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly-(ADP-ribose) polymerase. Nature. 2005; 434(7035):913–17p. [PubMed: 15829966]
Dobzhansky T. Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila pseudoobscura. Genetics. 1946; 31 (3):269–90p.
Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly-(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA. 2011; 108(8):3406–11p.
Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006; 25:5846–53p. [PubMed: 16998499]
Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10 (4): 293-301p.
Wang L, Mason KA, Ang KK, et al. MK- 4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012; 30(6):2113-20p.
Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med. 2005; 7(4):1–20p. [PubMed: 15836799]
McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly-(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16):8109–15p. [PubMed: 16912188]
Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010; 28(22):3555–61p.
Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCAdeficient advanced breast cancer. J Clin Oncol (Meeting Abstracts). 2009; 27(18S):CRA501.
Fong PC, Boss DS, Yap TA, et al. Inhibition of poly-(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123–34p. [PubMed: 19553641]
Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol. (Meeting Abstracts) 2009; 27(15S):5500.
Giaccone G, Rajan A, Kelly RJ, et al. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. J Clin Oncol. 2010; 28:15s. (suppl; abstr 3027).
Lee J, Annunziata CM, Minasian LM, et al. Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca). J Clin Oncol. 2011; 29 (suppl; abstr 2520).
Liu J, Fleming GF, Tolaney SM, et al. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. J Clin Oncol. 2011; 29 (suppl; abstr 5028).
Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2Hindazole-7-carboxamide (MK-4827): a novel oral poly-(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009; 52(22):7170–85p. [PubMed: 19873981]
Schelman WR, Sandhu SK, Moreno Garcia V, et al. First-in-human trial of a poly- (ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc). J Clin Oncol. 2011; 29 (suppl; abstr 3102).
Sandhu SK, Schelman WR, Wilding G, et al. The poly-(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013; 14(9):882-92p.
Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly- (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009; 27(16):2705–11p. [PubMed: 19364967]
LoRusso P, Ji JJ, Li J, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly-(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solidtumors. J Clin Oncol. 2011; 29 (suppl; abstr 3000).
Tan AR, Toppmeyer D, Stein MN, et al. Phase I trial of veliparib, (ABT-888), a poly-(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. J ClinOncol. 2011; 29 (suppl; abstr 3041).
Pishvaian MJ, Slack R, Witkiewicz A, et al. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pre-treated, metastatic colorectal cancer. J Clin Oncol. 2011; 29 (suppl; abstr 3502).
Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol. 2010; 28:15s. (suppl;abstr 1019)
Viswanathan S, Wesolowski R, Layman RM, et al. A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC). J Clin Oncol. 2011; 29 (suppl; abstr TPS106).
Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly- (ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer
Ther. 2007; 6:945–56p. [PubMed: 17363489]
Plummer R, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly-(ADPribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol. 2006; 24 (suppl; abstr 8013).
Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly-(ADPribose) polymerase inhibitor AG-014699. Br J Cancer. 2010; 103(10):1588–96p. [PubMed: 20978505]
Ali M, Telfer BA, McCrudden C, et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly-(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res. 2009; 15(19):6106–12. [PubMed: 19789326]
Hunter JE, Willmore E, Irving JA, et al. NF-κB mediates radio-sensitization by the PARP- inhibitor, AG-014699. Oncogene. 2012; 31(2): 251-64p.
Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 2008; 451:1111–5p. [PubMed: 18264088]
Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008; 451:1116–20p. [PubMed: 18264087]
Swisher E, Sakai W, Karlan B, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008; 68:2581–6p. [PubMed: 18413725]
DOI: https://doi.org/10.37628/ijaba.v1i1.37
Refbacks
- There are currently no refbacks.